

JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan's Leading Covid-19 Vaccine Produced by Adimmune

JHL is pleased to announce a signing of a MSA with Adimmune, a Taiwanese vaccine company, to manufacture the Antigen for their leading Covid-19 vaccine.

HSINCHU, TAIWAN, September 15, 2020 /EINPresswire.com/ -- [JHL Biotech](https://www.einpresswire.com/company/1234567890/), Inc. is extremely honored and proud to announce a signing of a Master Service Agreement ("MSA") with [Adimmune Corporation](https://www.adimmune.com/), a Taiwanese vaccine company, to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate. In full support of the Taiwan Government's diligence and awareness for Covid-19 prevention, as well as to ensure abundant vaccine doses for the Taiwanese population, Adimmune has been continually searching for qualified partners for commercial production of antigens, which led to a collaboration with JHL. Furthermore, since this pandemic is directly related to public health and national security, Adimmune and JHL are taking the opportunity to further build on a promising foundation by unifying locally developed production and supply chains to strengthen Taiwan's biotech industry overall.



JHL to manufacture antigen for Adimmune Covid-19 vaccine



JHL Biotech

This development and manufacturing agreement was initiated and advocated by James Huang,

the Executive Chairman and CEO of JHL Biotech, and Chi-Hsien Chan, M.D., the Chairman and CEO of Adimmune. In order to support Taiwan's already successful pandemic response initiative, Adimmune is currently collaborating with established companies such as JHL Biotech and continues to look for potential partners to further guarantee vaccine supply, for not only the Taiwanese people, but for other nations in need as well.

About JHL Biotech, Inc.

JHL is a biopharmaceutical company established in 2012 and after a transformation under new executive leadership led by James Huang, Chairman and CEO (also Managing Director of KPCB China), JHL continues to focus on three biotech sectors: 1) Accelerating the development programs for clients through the provision of Contract Development and Manufacturing Services (from cell line development to commercial manufacturing with regulatory filing support; 2) Developing a Proprietary Biosimilar Pipeline; and 3) Collaborating & Licensing of New and Innovative Biologics. For more information, please contact JHL at partnerwithjhl@jhlbiotech.com

About Adimmune Corporation

Founded in 1965, Adimmune Corporation (ADIM) is the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia, as well as the only PIC/S GMP manufacturer of human vaccines in Taiwan. ADIM's major products include Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin.

Urania Lee

JHL Biotech, Inc.

+886 36583899

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/526264478>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.